FDAnews Drug Daily Bulletin

Teijin Pharma to Launch Ipsen’s Somatuline Subcutaneous Injection in Japan

Jan. 18, 2013
Teijin Pharma and Ipsen announced the launch of Somatuline 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism (when response to surgical therapies is not satisfactory or surgical therapies are difficult to perform).